Table 5 Clinical characteristics and HRQoL measures by quartiles of VQ11 score
VQ11 quartiles | Q1(≤20) | Q2 (20–28) | Q3 (28–34.5) | Q4 (>34.5) | Scheffe ** | F | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(N = 45) | (N = 51) | (N = 37) | (N = 44) | P value $ | ||||||||||
Clinical characteristics | ||||||||||||||
Age (yrs) | 62.1 | ± | 9.1* | 60.9 | ± | 10.6 | 61.2 | ± | 11.0 | 61.6 | ± | 8.1 | 0.94 | |
BMI (kg/m2) | 25.3 | ± | 5.0 | 25.9 | ± | 4.7 | 25.0 | ± | 5.4 | 26.6 | ± | 6.3 | 0.55 | |
MMRC Dyspnea | 0.36 | ± | 0.77 | 1.23 | ± | 1.26 | 1.8 | ± | 1.2 | 2.4 | ± | 1.1 | Q1 < Q3; Q1 < Q2 < Q4 | <0.0001 |
Pre-BD FEV1 (ml) | 1676 | ± | 727 | 1413 | ± | 586 | 1176 | ± | 576 | 1267 | ± | 590 | Q1 < Q3,Q4 | 0.002 |
FEV1 (% pred) | 55.8 | ± | 18.7 | 51.4 | ± | 21.6 | 43.5 | ± | 19.2 | 44.2 | ± | 20.5 | NS | 0.013 |
FEV1/FVC (%) | 53.1 | ± | 10.3 | 47.5 | ± | 13.2 | 44.4 | ± | 11.7 | 45.5 | ± | 12.6 | Q1 < Q3,Q4 | 0.006 |
Dyspnea 6MWD end | 5.2 | ± | 1.9 | 6.1 | ± | 1.9 | 5.9 | ± | 2.1 | 6.7 | ± | 2.2 | Q1 < Q4 | 0.026 |
6MWT distance (m) | 521 | ± | 85.0 | 504 | ± | 119 | 449 | ± | 111 | 403 | ± | 132 | Q1,Q2 < Q4 | <0.0001 |
BODE | 1.8 | ± | 1.6 | 3.1 | ± | 1.9 | 4.2 | ± | 2.2 | 5.2 | ± | 2.4 | Q1,Q2 < Q4; Q1 < Q2,Q3 | <0.0001 |
HRQoL Measures | ||||||||||||||
SGRQ-C Symptoms | 43.1 | ± | 15.3 | 52.5 | ± | 17.1 | 59.1 | ± | 16.8 | 64.0 | ± | 20.0 | Q1 < Q3,Q4; Q2 < Q4 | <0.0001 |
SGRQ-C Activity | 38.9 | ± | 17.2 | 51.8 | ± | 19.4 | 60.7 | ± | 18.9 | 71.5 | ± | 21.9 | Q1 < Q2 < Q4; Q1 < Q3 | <0.0001 |
SGRQ-C Impact | 16.3 | ± | 9.2 | 31.6 | ± | 13.7 | 42.3 | ± | 16.8 | 48.9 | ± | 16.5 | Q1 < Q2 < Q3,Q4 | <0.0001 |
SGRQ-C Total | 28.9 | ± | 10.6 | 43.3 | ± | 13.5 | 53.4 | ± | 14.6 | 61.4 | ± | 17.0 | Q1 < Q2 < Q3,Q4 | <0.0001 |